Compare Herbalife Nutrition Ltd (HLF) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Sana Biotechnology Inc — how do they compare? Herbalife Nutrition Ltd trades at $12.04 (market cap $1.27B), while Sana Biotechnology Inc trades at $3.15 (market cap $873.84M). The key difference: Herbalife Nutrition Ltd is the larger of the two by market cap, and Herbalife Nutrition Ltd is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| HLF | SANA | |
|---|---|---|
Market Cap | $1.27B | $873.84M |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $5.92 |
52-Week Low | $7.75 | $2.68 |
Enterprise Value | $3.00B | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $12.25, up 2.17% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.64, beating expectations, and raised full-year guidance. Revenue remains stable around $5 billion annually, with a net income margin of 4.66%. Valuation ratios appear attractive with a P/E of 5.26 and P/S of 0.25. Debt-to-asset ratio improved to 71.67% in 2025, reflecting progress in deleveraging.
The outlook is mixed: strong analyst support (57.69% buy ratings) and operational improvements contrast with high debt levels and negative shareholder equity. Key risks include competitive pressures and reliance on international growth. Near-term catalyst is Q2 2026 earnings on August 5, 2026.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
